These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 804129)

  • 1. Letter: Prednisone dose in alternate-day therapy.
    Reischer M
    N Engl J Med; 1975 Mar; 292(10):533. PubMed ID: 804129
    [No Abstract]   [Full Text] [Related]  

  • 2. Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections.
    Dale DC; Fauci AS; Wolff SM
    N Engl J Med; 1974 Nov; 291(22):1154-8. PubMed ID: 4609038
    [No Abstract]   [Full Text] [Related]  

  • 3. Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation.
    Pedrosa MC; Rohrer RM; Kaplan MM
    Clin Transplant; 1995 Aug; 9(4):322-5. PubMed ID: 7579741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [10-day dynamics of granulocytic responses in peripheral blood in patients treated with prednisone].
    Prokopowicz D
    Wiad Lek; 1975 Apr; 28(8):635-42. PubMed ID: 1130064
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of alternate day steroids and daily steroids in renal transplant recipients.
    Davisson NA; Westervelt FB; Bolton WK
    Proc Clin Dial Transplant Forum; 1980; 10():150-4. PubMed ID: 7050977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Drugs and phagocytes.
    Cline MJ
    N Engl J Med; 1974 Nov; 291(22):1187-8. PubMed ID: 4423081
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of alternate-day prednisone therapy on cortisol secretion rate in corticosteroid-dependent asthmatics.
    Bakran I; Korsić M; Duraković Z; Vrhovac B; Tajić M
    Int J Clin Pharmacol Biopharm; 1977 Feb; 15(2):57-60. PubMed ID: 328415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
    Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of single-dose alternate-day prednisone therapy on the immunological status of patients with neuromuscular diseases.
    Cook JD; Trotter JL; Engel WK; Sciabbarrasi JS
    Ann Neurol; 1978 Feb; 3(2):166-76. PubMed ID: 306799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of prednisone dose spacing on plasma lipids.
    Galla JH; Curtis JJ; Woodford SY; Rees ED; Somes GW; Luke RG
    J Lab Clin Med; 1980 Jun; 95(6):801-7. PubMed ID: 6991620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
    Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenocortical suppression in dogs on daily and alternate-day prednisone administration.
    Chastain CB; Graham CL
    Am J Vet Res; 1979 Jul; 40(7):936-41. PubMed ID: 507496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of refractory Evans syndrome with alternate-day cyclosporine and prednisone.
    Rackoff WR; Manno CS
    Am J Pediatr Hematol Oncol; 1994 May; 16(2):156-9. PubMed ID: 8166369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose alternate-day prednisone for persistent Wells' syndrome.
    Coldiron BM; Robinson JK
    Arch Dermatol; 1989 Dec; 125(12):1625-6. PubMed ID: 2589856
    [No Abstract]   [Full Text] [Related]  

  • 15. Alternate-day prednisone therapy for pemphigus vulgaris. Preliminary report.
    Rabhan NB; Kopf AW
    Arch Dermatol; 1971 Jun; 103(6):615-22. PubMed ID: 5555849
    [No Abstract]   [Full Text] [Related]  

  • 16. Alternate-day prednisone therapy. Evaluation of delayed hypersensitivity responses, control of disease and steroid side effects.
    MacGregor RR; Sheagren JN; Lipsett MB; Wolff SM
    N Engl J Med; 1969 Jun; 280(26):1427-31. PubMed ID: 4306760
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation.
    Miao L; Sun J; Yuan H; Jia Y; Xu Z
    Nephrology (Carlton); 2006 Oct; 11(5):449-54. PubMed ID: 17014560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks of alternate-day prednisone in patients with cystic fibrosis.
    Rosenstein BJ; Eigen H
    Pediatrics; 1991 Feb; 87(2):245-6. PubMed ID: 1987537
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975.
    Lever WF; Schaumburg-Lever G
    Arch Dermatol; 1977 Sep; 113(9):1236-41. PubMed ID: 900969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Indications for alternate-day immunosuppressive therapy in dermatology].
    Barthelmes H; Tausch I; Haustein UF
    Przegl Dermatol; 1975; 62(4):523-30. PubMed ID: 1162101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.